News2 – Page 3 – Verséa
 

News2

Sean Fetcho, the co-founder and CEO of Verséa Holdings, Inc. announced as a Tampa Bay Business Journal 40 under 40 honoree

Sean Fetcho, the co-founder and CEO of Verséa Holdings, Inc. (“Verséa”) has been announced as a Tampa Bay Business Journal 40 under 40 honoree. This is the most competitive award given by the Tampa Bay Business Journal, with over 500 nominations this year alone. The award recognizes exceptional business professionals, leaders and innovators under the...

Verséa Holdings, Inc. welcomes Rob Sambursky, MD, as President  to lead the company’s expansion into the ophthalmic market

Verséa Holdings, Inc. (“Verséa”) welcomes Rob Sambursky, MD, who joined the company as the President, effective as of August 5, 2022. Dr. Sambursky will support corporate strategy and operations as well as lead the company’s expansion into the ophthalmic market. Verséa recently launched a new business division, Verséa Ophthalmics, with a goal of providing innovative...

Successful first validation test on VCX™ Discovery Platform at UCSD Biomedical Lab

Verséa Discovery successfully ran its first validation test assays at the UCSD Biomedical Lab using its proprietary VCX™ Discovery Platform   The cellular based platform VCX™ Discovery Platform follows a proprietary process developed by Verséa Discovery. Through machine learning, the system links highly specific cellular functions (focused on mitochondrial biology and second messenger signaling) to...

Cannabinol (CBN) shows unique therapeutic potential in glaucoma

A recently published peer-reviewed scientific article “Cannabinol Modulates Neuroprotection and Intraocular Pressure: A Potential Multi-Target Therapeutic Intervention for Glaucoma” has provided insight into unique therapeutic potential of Cannabinol (CBN) for glaucoma treatment   The article, published in a leading international journal Biochimica et Biophysical Acta (BBA – Molecular Basis of Disease) (LINK to the article)...

2 new COVID symptoms reported for BA.2 omicron variant

According to recent reports, the new BA.2 COVID-19 variant (a subvariant of the omicron variant called BA.1.) spreads more easily than the original omicron. Early data suggest that BA.2 is about 30% more transmissible than the original variant. The new BA.2 variant can also manifest different symptoms than the original strains. New symptoms include: Dizziness Fatigue...

Omicron variants – Statement from the WHO

Yesterday the WHO’s Technical Advisory Group on SARS-Cov-2 Virus Evolution (ATG-VE) published a statement on new omicron variants that have been circulating globally, accounting for nearly all sequences reported to GISAID: “Based on available data of transmission, severity, reinfection, diagnostics, therapeutics and impacts of vaccines, the group reinforced that the BA.2 sublineage should continue to...

New Study Identifies Top-Performing Point-of-Care COVID-19 Tests

Researchers screen rapid-detection COVID-19 tests for sensitivity/specificity, limit of detection, and time to results ANN ARBOR, MI, and VANCOUVER, BC—February 10, 2021—After screening more than 1,100 independently assessed, point-of-care COVID-19 tests, researchers at NSF International and Novateur Ventures have identified five direct (antigen/RNA) tests for detection of acute infection and six indirect (antibody) tests for...

Collaboratively administrate turnkey channels whereas virtual e-tailers. Objectively seize scalable metrics whereas proactive e-services. Dynamically procrastinate B2C users after installed base benefits. Dramatically visualize customer directed convergence without revolutionary ROI.